A clinical trial is being conducted to evaluate the safety, tolerance, and pharmacokinetics (PK) of IDE034 in Phase 1 dose escalation. IDE034 is being tested both as a standalone treatment and in conjunction with the company's exclusive PARG inhibitor, IDE161. The target population includes patients with various solid tumor types, with B7H3/PTK7 expression observed in 30-40% of cases. Tumor types under investigation include lung, breast, ovarian, and colorectal cancer.